Skip to main content

Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

Written by Customer Service on . Posted in Public Companies.

RADNOR, Pa., Nov. 27, 2019 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in Baltimore, Maryland on December 7 and 8, 2019. 
Details for the poster presentations at the AES Annual Meeting:“Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus” R.E. Ramsay, et al.
Abstract # 1.136 
Saturday, December 7
12:00 pm to 6:00 pm“Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects” A.M. Hussain, et al.
Abstract # 2.213 
Saturday, December 7
12:00 pm to 6:00 pmIn addition to the Main Exhibit Hall session, Abstract 1.136 was accepted for presentation at the Investigator’s Workshop Poster Session, which highlights the most outstanding abstracts on topics related to basic science and clinical research.  Details for this presentation:What: Investigator’s Workshop Poster Session
Where: Baltimore Convention Center, Room 339 – 342, Level 300
When: Sunday December 8, 2019, 12pm-1:30pmKOL Breakfast and Live Webcast:  Update on Ganaxolone for the Treatment of Refractory Status Epilepticus (RSE)Marinus will host a KOL breakfast meeting at AES which will feature presentations by Michael A. Rogawski, MD, PhD (University of California, Davis), key opinion leader in the field of neurosteroids, as well as Joe Hulihan, MD (Chief Medical Officer of Marinus). Members of the Company’s  management team will also present further information on its recently completed Phase II trial of ganaxolone in RSE. This event is intended for institutional investors and sell-side analysts. Please RSVP in advance if you plan to attend, as space is limited.Where: Royal Sonesta Harbor Court, 550 Light Street Baltimore, MD
When: Monday, December 9, 7am to 8.30am ETFor those who are unable to attend in person, a live webcast with slides and replay of the event will be accessible here. About Marinus PharmaceuticalsForward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical study testing schedule and milestones, the ability to complete enrollment in our clinical studies, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, the timing of the clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, the attainment of clinical study results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.       
CONTACT:
Lisa M. Caperelli
Executive Director, Investor & Strategic Relations
Marinus Pharmaceuticals, Inc.
484-801-4674

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.